This content is machine translated SID Annual Meeting: Highlights Update on inflammatory dermatoses – a concentrated load of innovative power Research teams from different corners of the world presented studies that are characterized by a high level of innovation. In addition to the evaluation of already established therapy options, numerous...…
View Post 8 min This content is machine translated Psoriasis and PsA Biologics, oral peptide and trivalent nanobody – current results and trends Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from...…
View Post 5 min This content is machine translated Psoriasis Indications of an increased risk of “leaky gut” Psoriasis sufferers often have invisible inflammation in the small intestine along with a tendency to increased permeability of the intestinal barrier (“leaky gut”), according to recently published research from Uppsala...…
View Post 8 min This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 9 min This content is machine translated Psoriasis in locations that are difficult to treat New study data on IL-23 inhibition When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved...…
View Post 4 min This content is machine translated Inflammatory memory in psoriasis Timing of biologics therapy is crucial The pathogenesis of psoriasis is complex, but is becoming increasingly better understood. With the modern substance classes of interleukin (IL)-17 and IL-23 inhibitors, highly effective biologics are now available for…
View Post 5 min This content is machine translated SDNTT register data Psychological comorbidities in psoriasis Inflammatory systemic diseases such as psoriasis are associated with a high risk of comorbidity. In addition to cardiometabolic diseases, mental disorders are particularly common in this patient population. As part…
View Post 9 min This content is machine translated System therapy for psoriasis Expanded possibilities thanks to practical innovations Compared to the past, there are now more and more effective systemic therapies available. This has been helped by a surge in innovation that has produced a wide range of…
View Post 7 min This content is machine translated Systemic disease psoriasis Keep an eye on comorbidities Comorbidities may already be present at the initial manifestation of plaque psoriasis, but sometimes these only develop later in the course of the disease. Taking this into account appropriately can…
View Post 4 min This content is machine translated "Psoriasis and Beyond" Insight into the patient’s perspective In order to better understand the experiences and views of patients affected by psoriasis and psoriatic arthritis, a survey of almost 5,000 patients was conducted on four continents worldwide.One focus…
View Post 4 min This content is machine translated TYK2 inhibition in psoriasis What’s new? The JAK-STAT pathway mediates a variety of proinflammatory responses through Janus kinases (JAK)1-3 andtyrosine kinase-2 (TYK2).Deucravacitinib selectively inhibits TYK2 and was shown to be effective and safe in patients with…
